

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Xuanzhu Biopharmaceutical Co., Ltd.**

**軒竹生物科技股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2575)**

**VOLUNTARY ANNOUNCEMENT**  
**RESULTS OF PRELIMINARY DATA FROM THE PHASE 1B FORTRESS**  
**CLINICAL STUDY OF NG-350A PRESENTED AT THE 2026 AACR**

The board of directors (the “**Board**”) of Xuanzhu Biopharmaceutical Co., Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that preliminary results from the Phase 1b FORTRESS study of NG-350A were presented at the 2026 Annual Meeting of the American Association for Cancer Research (AACR) on April 20, 2026. NG-350A, an oncolytic immunotherapy being developed for the treatment of mismatch repair-proficient (pMMR) locally advanced rectal cancer (LARC), was in-licensed by the Group from Akamis Bio, Inc. (“**Akamis**”), a clinical-stage oncology company working to advance the standard of care in colorectal cancer.

The Phase 1b FORTRESS study (NCT06459869) is an open-label, single-arm, and multi-center trial of NG-350A in combination with chemoradiotherapy (CRT) in adult patients with pMMR LARC and at least one risk factor for local or distant recurrence or with oligometastatic disease. The ongoing study is assessing the anti-tumor effects of NG-350A combined with CRT following a 12-week active treatment period to establish whether NG-350A can improve composite response rates – defined as the proportion of patients achieving a clinical complete response (cCR) or a near clinical complete response (ncCR) – in pMMR LARC patients relative to expected outcomes from CRT alone.

The benchmark composite response rate (cCR + ncCR) with CRT alone at 12 weeks is approximately 25 percent. The study results demonstrate a 50 percent composite response rate in the first 10 patients who completed the 12-week active treatment period, with no serious adverse events or new safety signals identified related to NG-350A. These early data highlight the potential of NG-350A in combination with CRT to improve outcomes in patients with pMMR LARC compared with CRT alone.

## **ABOUT NG-350A**

NG-350A is a clinical-stage, intravenously delivered Tumor-Specific Immuno-Gene (T-SIGn<sup>®</sup>) therapeutic designed to drive intratumoral expression of a CD40 agonist monoclonal antibody triggering the activation of antigen-presenting cells (APCs) resident in solid tumors and their draining lymph nodes. Once activated, APCs recruit T cells into the vicinity of the tumor to deliver a potent anti-tumor immune response. Akamis has evaluated NG-350A's safety, tolerability, and preliminary efficacy as a monotherapy (FORTITUDE study) and in combination with pembrolizumab (FORTIFY study) in patients with metastatic or advanced epithelial tumors. Across these studies, NG-350A has demonstrated a consistent safety and tolerability profile, as well as strong evidence of tumor-selective delivery, replication and transgene expression.

The Group holds exclusive rights to the development, manufacturing and commercialization of NG-350A in Greater China. The Company is actively advancing the application for clinical trials of NG-350A in the People's Republic of China ("PRC"). For details of the license agreement with Akamis and NG-350A, see "Business – Our License and Asset Acquisition Arrangements – Our Inlicensing and Asset Acquisition Agreements – Agreement with Akamis to In-license an Oncolytic Viral Vector Asset" in the prospectus of the Company dated October 6, 2025.

## **ABOUT AKAMIS**

Headquartered in Cambridge, Massachusetts, Akamis is a clinical-stage oncology company developing systemically administered oncolytic immunotherapies to treat colorectal cancer, initially in patients with locally advanced rectal cancer (LARC). Its proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn<sup>®</sup>) platform is designed to deliver novel immunotherapeutic proteins, biomolecules and transgene combinations to treat solid tumors, with its lead clinical-stage program, NG-350A, driving intratumoral expression of a CD40 agonist monoclonal antibody.

By order of the Board

**Xuanzhu Biopharmaceutical Co., Ltd.**

**Ms. Xu Yanjun**

*Chairperson of the Board and executive Director*

Hong Kong, April 20, 2026

*As of the date of this announcement, the Board comprises (i) Ms. Xu Yanjun, Dr. Li Jia Kui and Dr. Shih Cheng-Kon as executive directors; (ii) Ms. Li Huiying, Mr. Yu Lifeng and Ms. Chen Yanling as non-executive directors; and (iii) Mr. Liu Shuo, Ms. Wang Yu and Mr. Fan Chi Chiu as independent non-executive directors.*